Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of AT-02

NCT05951049 is registered in ClinicalTrials.gov with Attralus, Inc. as lead sponsor.

NCT NCT05951049
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05951049 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of AT-02
Lead sponsor
Attralus, Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 21, 2023
Completion date
September 28, 2026
Enrollment
120 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

amyloidosis; systemic